Enjamb Labs builds full-stack AI agents that accelerate biopharma R&D by unifying drug development workflows in a single auditable workspace. Its agents operate across preclinical research through clinical trials and regulatory approval, synthesizing clinical evidence, drafting regulatory documents such as INDs, protocols, and NDAs, and executing statistical programming tasks. The company was founded by Maadhav Deekshitha and Rayan Mubarak, who bring machine learning and neuroscience research backgrounds. Enjamb Labs is based in San Francisco and is part of Y Combinator's Spring 2026 batch.
Enjamb Labs
ActiveFull stack AI Agents accelerating Biopharma R&D
Total raised
$500K
1 round
Stage
Seed
Jan 2026
Team
1-10
since 2026
Pricing
—
Founded
2026
San Francisco, United States
Agent-ready
—
Full-stack AI agents for biopharma R&D
Unifies drug development workflows in a single auditable workspace
Coverage from preclinical research through clinical trials and regulatory approval
Synthesizes clinical evidence across studies
Drafts regulatory documents including INDs, protocols, and NDAs
Executes statistical programming tasks
Auditable workspace supporting traceability of work
Agentic automation across the drug development lifecycle
12/100
Early
MCP server
Public API
Webhooks
OAuth 2.0
SDKs
No public agent surfaces detected yet.
Jan 2026 Seed $500K ● Y Combinator
Capital network
$500K raised ·1 backer·10 network links
- Backers1
- Shared portfoliocompanies these backers also fund
- Extended networkfunds that co-invest alongside them
Isomorphic Labs
Drug Discovery
Treeline Biosciences
Computational and experimental drug discovery for hard-to-drug cancer targets
AI MedicalDrug Discovery
Terray Therapeutics
Generative AI and ultra-high-throughput chemistry for small-molecule drug discovery
AI HealthcareDrug Discovery
Genesis Molecular AI
Generative AI for small-molecule drug discovery
AI HealthcareDrug Discovery
Basecamp Research
Building a GPT for biology from the planet's largest proprietary genomic dataset
Drug Discovery
Nabla Bio
Generative AI for de novo antibody and protein design against tough drug targets
Drug Discovery
- What does Enjamb Labs build?
- It builds full-stack AI agents that accelerate biopharma R&D by unifying drug development workflows in a single auditable workspace, spanning preclinical research through regulatory approval.
- Which documents can its agents draft?
- Its agents can draft regulatory documents such as INDs, protocols, and NDAs, in addition to synthesizing clinical evidence and executing statistical programming tasks.
- Why is the workspace described as auditable?
- An auditable workspace supports traceability of the agents' work, which matters in the heavily regulated drug development process.
- Who founded Enjamb Labs?
- It was founded by Maadhav Deekshitha and Rayan Mubarak, who bring machine learning and neuroscience research backgrounds. The company is San Francisco-based and part of YC's Spring 2026 batch.
Discussion
Sign in to join the discussion.
Sign inExplore more around Enjamb Labs
Contextual paths to related AI startups, deals and rankings.